WO2007056099A2 - Inhibiteurs de canaux ioniques - Google Patents

Inhibiteurs de canaux ioniques Download PDF

Info

Publication number
WO2007056099A2
WO2007056099A2 PCT/US2006/042882 US2006042882W WO2007056099A2 WO 2007056099 A2 WO2007056099 A2 WO 2007056099A2 US 2006042882 W US2006042882 W US 2006042882W WO 2007056099 A2 WO2007056099 A2 WO 2007056099A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
heterocycloalkyl
cycloalkyl
member selected
Prior art date
Application number
PCT/US2006/042882
Other languages
English (en)
Other versions
WO2007056099A3 (fr
Inventor
Xiaodong Wang
Alan Fulp
Brian Marron
Serge Beaudoin
Darrick Seconi
Mark Suto
Original Assignee
Icagen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen, Inc. filed Critical Icagen, Inc.
Priority to EP06827413A priority Critical patent/EP1945029A4/fr
Priority to AU2006311954A priority patent/AU2006311954A1/en
Priority to JP2008539041A priority patent/JP2009514868A/ja
Priority to CA002628312A priority patent/CA2628312A1/fr
Publication of WO2007056099A2 publication Critical patent/WO2007056099A2/fr
Publication of WO2007056099A3 publication Critical patent/WO2007056099A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • This invention relates to the use of certain compounds as sodium channel blockers and to the treatment of pain by the inhibition of sodium channels. Additionally, this invention relates to novel compounds that are useful as sodium channel blockers.
  • Voltage-gated sodium channels are found in all excitable cells including myocytes of muscle and neurons of the central and peripheral nervous system. In neuronal cells sodium channels are primarily responsible for generating the rapid upstroke of the action potential. In this manner sodium channels are essential to the initiation and propagation of electrical signals in the nervous system. Proper and appropriate function of sodium channels is therefore necessary for normal function of the neuron. Consequently, aberrant sodium channel function is thought to underlie a variety of medical disorders (See Hubner CA, Jentsch TJ, Hum. MoI. Genet, 11(20): 2435-45 (2002) for a general review of inherited ion channel disorders) including epilepsy (Yogeeswari et ah, Curr.
  • VGSC voltage-gated sodium channel
  • SCNx SCNx
  • SCNAx SCNx
  • Na v x.x The VGSC family has been phylogenetically divided into two subfamilies Na v l.x (all but SCN6A) and Na v 2.x (SCN6A).
  • the Navl.x subfamily can be functionally subdivided into two groups, those which are sensitive to blocking by tetrodotoxin (TTX-sensitive or TTX-s) and those which are resistant to blocking by tetrodotoxin (TTX-resistant or TTX-r).
  • SCN5A gene product Na v l .5, Hl
  • the SCN5A gene product is almost exclusively expressed in cardiac tissue and has been shown to underlie a variety of cardiac arrhythmias and conduction disorders (Liu H, et ah, Am. J. Pharmacogenomics, 3(3): 173-9 (2003)). Consequently, blockers of Navl.5 have found clinical utility in treatment of such disorders (Srivatsa U, et ah, Curr. Cardiol. Rep., 4(5): 401-10 (2002)).
  • TTX-resistant sodium channels Navl .8 (SCNlOA, PN3, SNS) and Navl .9 (SCNl IA, NaN, SNS2) are expressed in the peripheral nervous system and show preferential expression in primary nociceptive neurons.
  • Human genetic variants of these channels have not been associated with any inherited clinical disorder.
  • aberrant expression of Navl .8 has been found in the CNS of human multiple sclerosis (MS) patients and also in a rodent model of MS (Black, JA, et ah, Proc. Natl. Acad. ScI USA, 97(21): 11598-602 (2000)).
  • the TTX-sensitive subset of voltage-gated sodium channels is expressed in a broader range of tissues than the TTX-resistant channels and has been associated with a variety of human disorders.
  • the Na v l .1 channel well exemplifies this general pattern, as it is expressed in both the central and peripheral nervous system and has been associated with several seizure disorders including Generalized Epilepsy with Febrile Seizures Plus, types 1 and 2 (GEFS+1, GEFS+2), Severe Myoclonic Epilepsy of Infancy (SMEI), and others (Claes, L, et al, Am. J. Hum. Genet., 68: 1327-1332 (2001); Escayg, A., Am. J. Hum.
  • Navl .2 The Navl .2 channel is largely, if not exclusively, expressed in the central nervous system and quantitative studies indicate it is the most abundant VGSC of the CNS. Mutations of Navl.2 are also associated with seizure disorders (Berkovic, S. F., et al., Ann. Neurol, 55: 550-557 (2004)) and Navl.2-null "knockout" mice exhibit perinatal lethality (Planells-Cases R et al, Biophys. J, 78(6):2878- 91 (2000)).
  • Navl.4 expression of the Navl.4 gene is largely restricted to skeletal muscle and, accordingly, mutations of this gene are associated with a variety of movement disorders (Ptacek, L. J., Am. J. Hum. Genet., 49: 851-854 (1991); Hudson AJ, Brain, 118(2): 547-63 (1995)). The majority of these disorders are related to hyperactivity or "gain-of-function" and have been found to respond to treatment with sodium channel blockers (Desaphy JF, et al, J. Physiol, 554(2): 321-34 (2004)).
  • SCN3A nor the SCN8A VGSC genes have been conclusively linked to heritable disorders in humans.
  • Loss-of-function mutations of the SCN8A gene are known in mice and yield increasingly debilitating phenotypes, dependent upon the remaining functionality of the gene products (Meisler MH, Genetica, 122(1): 37-45 (2004)).
  • Homozygous null mutations cause progressive motor neuron failure leading to paralysis and death, while heterozygous null animals are asymptomatic.
  • Homozygous med mice have nearly 90% reduction in functional Navl.6 current and exhibit dystonia and muscle weakness but are still viable.
  • Navl.6 is expressed at high levels in dorsal root ganglia and can be found in spinal sensory tracts (Tzoumaka E, J. Neurosci. Res., 60(1): 37-44 (2000)). It should be noted however that expression of Navl.6 is not restricted to sensory neurons of the periphery. Like the Navl.6 channel, expression of the Navl.3 VGSC can also be detected in both the central and peripheral nervous system, though levels in the adult CNS are generally much higher than PNS.
  • Navl .3 During development and the early postnatal period Navl .3 is expressed in peripheral neurons but this expression wanes as the animal matures (Shah BS, Physiol, 534(3): 763-76 (2001); Schaller KL, Cerebellum, 2(1): 2-9 (2003)). Following neuronal insult Navl.3 expression is upregulated, more closely mimicking the developmental expression patterns (Hains BC, J. Neurosci. , 23(26): 8881 -92 (2003)). Coincident with the recurrence of Navl.3 expression is the emergence of a rapidly re-priming sodium current in the injured axons with a biophysical profile similar to Navl .3 (Leffler A, et al, J.
  • the Na v l .7 (PNl , SCN9A) VGSC is sensitive to blocking by tetrodotoxin and is preferentially expressed in peripheral sympathetic and sensory neurons.
  • the SCN9A gene has been cloned from a number of species, including human, rat, and rabbit and shows ⁇ 90 % amino acid identity between the human and rat genes (Toledo-Aral et ah, Proc. Natl. Acad. Sd. DS4, 94(4): 1527-1532 (1997)).
  • Na v l .7 may play a key role in various pain states, including acute, inflammatory and/or neuropathic pain.
  • Na v 1.7 protein has been shown to accumulate in neuromas, particularly painful neuromas (Kretschmer et ah, Acta. Neurochir. (Wien), 144(8): 803-10 (2002)).
  • Sodium channel-blocking agents have been reported to be effective in the treatment of various disease states, and have found particular use as local anesthetics and in the treatment of cardiac arrhythmias. It has also been reported that sodium channel-blocking agents may be useful in the treatment of pain, including acute, chronic, inflammatory and/or neuropathic pain; see, for example, Wood, JN et al, J. Neurobioh, 61(1): 55-71 (2004). Preclinical evidence demonstrates that sodium channel-blocking agents can suppress neuronal firing in peripheral and central sensory neurons, and it is via this mechanism that they may be useful for relieving pain. In some instances abnormal or ectopic firing can originate from injured or otherwise sensitized neurons.
  • sodium channels can accumulate in peripheral nerves at sites of axonal injury and may function as generators of ectopic firing (Devor et al J. Neurosci, 132: 1976 (1993)). Changes in sodium channel expression and excitability have also been shown in animal models of inflammatory pain where treatment with proinflammatory materials (CFA, Carrageenan) promoted pain-related behaviors and correlated with increased expression of sodium channel subunits (Gould et al, Brain Res., 824(2): 296-9 (1999); Black et al, Pain, 108(3): 237-47 (2004)). Alterations in either the level of expression or distribution of sodium channels, therefore, may have a major influence on neuronal excitability and pain-related behaviors.
  • CFA proinflammatory material
  • Ohkawa et al have described a class of cyclic ethers that are of use as sodium channel blockers (U.S. Patent No. 6,172,085).
  • gabapentin is the principal treatment for neuropathic pain. As with epilepsy, its mechanism of action for pain is unknown. However, as little as only 30% of patients respond to gabapentin treatment for neuropathic pain.
  • the present invention provides compounds that are useful in the treatment of diseases through the modulation of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides compounds, compositions and methods that are useful in ameliorating or alleviating conditions susceptible to such ion channel modulation as more fully described below.
  • the invention provides a compound according to Formula I:
  • R 1 , R 2 , R 3 and R 4 are independently selected from H 3 F, CF 3 , substituted or unsubstituted C 1 -C 4 alkyl, unsubstituted 4- to 7- membered cycloalkyl and unsubstituted 4- to 7- membered heterocycloalkyl.
  • the symbol A represents a member selected from:
  • R 5 is selected from C 1 -C 4 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 6 and R 6 are independently selected from H, C 1 -C 4 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 5 and R 6 are optionally joined to form a member selected from a substituted or unsubstituted cycloalkyl moiety or a substituted or unsubstituted heterocycloalkyl moiety.
  • the symbol B represents a member selected from:
  • the symbol X represents a member selected from O and S.
  • the symbol Y represents a member selected from CH and N.
  • the index s represents an integer greater than 0, sufficient to satisfy the valence requirements of the ring atoms.
  • Each R 7 is independently selected from H, OR 8 , NR 9 R 10 , SO 2 NR 9 R 10 , cyano, halogen, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 8 is selected from H, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 9 and R 10 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • s is 1 and R 7 is a member selected from chloro and fluoro.
  • s is 2 and each R 7 is a member independently selected from chloro and fluoro.
  • s is 2 and each R 7 is fluoro.
  • B is
  • the symbol Z is a member selected from:
  • Each R 11 is a member independently selected from H, OR 13 , NR 14 R 15 , SO 2 NR 14 R 15 , cyano, halogen, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 13 is a member selected from H, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 14 and R 15 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 14 and R 15 together with the nitrogen to which they are bound, can be optionally joined to form a substituted or unsubstituted 5- to 7-membered ring.
  • the index r represents a member selected from the integers from 0 to 2.
  • the index p represents a member selected from the integers from 0 to 1.
  • R 12 is selected from H, C 1 -C 4 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • the indices m and n independently represent an integer selected from 0 to 2, such that when a member selected from m and n can be greater than 1, each R 1 and R 2 ; R 3 and R 4 , respectively, can be independently selected.
  • the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound as provided above.
  • the present invention provides a method for modulating the activity of a sodium channel in a subject, comprising administering to a subject an amount of a compound as provided above which is sufficient to modulate the activity.
  • the present invention provides a method of ameliorating or alleviating a condition in a subject.
  • the condition can be a member selected from, among others, pain, irritable bowel syndrome, Crohn's disease, epilepsy, seizures multiple sclerosis, bipolar depression and tachyarrhythmias.
  • the method comprises administering to the subject an amount of a compound of the invention sufficient to ameliorate or alleviate said condition.
  • CHO Chinese hamster ovary
  • EBSS Earl's Balanced Salt Solution
  • SDS sodium dodecyl sulfate
  • Et 3 N triethylamine
  • MeOH methanol
  • DMSO dimethylsulfoxide
  • pain refers to all categories of pain, including pain that is described in terms of stimulus or nerve response, e.g., somatic pain (normal nerve response to a noxious stimulus) and neuropathic pain (abnormal response of a injured or altered sensory pathway, often without clear noxious input); pain that is categorized temporally, e.g., chronic pain and acute pain; pain that is categorized in terms of its severity, e.g., mild, moderate, or severe; and pain that is a symptom or a result of a disease state or syndrome, e.g., inflammatory pain, cancer pain, AIDS pain, arthropathy, migraine, trigeminal neuralgia, cardiac ischaemia, and diabetic neuropathy (see, e.g., Harrison's Principles of Internal Medicine, pp. 93-98 (Wilson et al, eds., 12th ed. 1991); Williams et al, J. of Med. Chem. 42: 1481-14
  • Somatic pain refers to a normal nerve response to a noxious stimulus such as injury or illness, e.g., trauma, burn, infection, inflammation, or disease process such as cancer, and includes both cutaneous pain (e.g., skin, muscle or joint derived) and visceral pain (e.g., organ derived).
  • a noxious stimulus such as injury or illness, e.g., trauma, burn, infection, inflammation, or disease process such as cancer
  • cutaneous pain e.g., skin, muscle or joint derived
  • visceral pain e.g., organ derived
  • Neuroopathic pain refers to pain resulting from injury to or chronic changes in peripheral and/or central sensory pathways, where the pain often occurs or persists without an obvious noxious input.
  • Acute pain refers to pain which is marked by short duration or a sudden onset.
  • Chronic pain refers to pain which is marked by long duration or frequent recurrence.
  • Inflammatory pain refers to pain which is produced as a symptom or a result of inflammation or an immune system disorder.
  • Visceral pain refers to pain which is located in an internal organ.
  • Bio medium refers to both in vitro and in vivo biological milieus.
  • exemplary in vitro “biological media” include, but are not limited to, cell culture, tissue culture, homogenates, plasma and blood. In vivo applications are generally performed in mammals, preferably humans.
  • Compound of the invention refers to the compounds discussed herein, pharmaceutically acceptable salts and prodrugs of these compounds.
  • Inhibiting and blocking are used interchangeably herein to refer to the partial or full blockade of a voltage sodium gated channel by a compound of the invention, which leads to a decrease in ion flux either into or out of a cell in which a voltage-gated sodium channel is found.
  • substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, e.g., -CH 2 O- is intended to also recite -OCH 2 -.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. C 1 -C 10 means one to ten carbons).
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n- hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • alkyl groups examples include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4- pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • alkyl unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as “heteroalkyl.”
  • Alkyl groups that are limited to hydrocarbon groups are termed "homoalkyl".
  • alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH 2 CH 2 CH 2 CH 2 -, and further includes those groups described below as “heteroalkylene.”
  • an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
  • a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom selected from the group consisting of O, N and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of tne molecule.
  • Up to two heteroatoms may be consecutive, such as, for example, -CH 2 -NH-OCH 3 .
  • heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S- CH 2 -CH 2 -NH-CH 2 -.
  • heteroalkylene groups heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
  • no orientation of the linking group is implied by the direction in which the formula of the linking group is written.
  • the formula -C(O) 2 R'- represents both -C(O) 2 R'- and -R 5 C(O) 2 -.
  • cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3- cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl examples include, but are not limited to, 1 -(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4- morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 -piperazinyl, 2-piperazinyl, and the like.
  • halo or halogen
  • substituents mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
  • haloalkyl are meant to include monohaloalkyl and polyhaloalkyl.
  • ImIo(C 1 -C 4 )alkyl is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • aryl means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently.
  • heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
  • a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2- phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalin
  • aryl when used in combination with other terms (e.g. , aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above.
  • arylalkyl is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyloxy)propyl, and the like).
  • alkyl group e.g., benzyl, phenethyl, pyridylmethyl and the like
  • an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyl
  • R', R", R" 5 and R" 5 ' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
  • each of the R groups is independently selected as are each R', R", R 555 and R 5555 groups when more than one of these groups is present.
  • R' and R 55 are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7- membered ring.
  • -NR'R is meant to include, but not be limited to, 1- pyrrolidinyl and 4-morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g. , -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like).
  • substituents for the aryl and heteroaryl groups are generically referred to as "aryl group substituents.”
  • R', R", R'" and R 5 " 5 are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • each of the R groups is independently selected as are each R 5 , R 55 , R' 55 and R"" groups when more than one of these groups is
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR 5 ) q -U-, wherein T and U are independently -NR-, -0-, -CRR 5 - or a single bond, and q is an integer of from O to 3.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CRR 5 -, -0-, -NR-, -S-, -S(O)-, -S(O) 2 -, -S(O) 2 NR 5 - or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - (CRR') s -X-(CR"R'")d-, where s and d are independently integers of from O to 3, and X is -O- , -NR 5 -, -S-, -S(O)-, -S(O) 2 -, or -S(O) 2 NR'-.
  • the substituents R, R 5 , R" and R 5 " are preferably independently selected from hydrogen or substituted or unsubstituted (Ci-C 6 )alkyl.
  • heteroatom includes oxygen (O), nitrogen (N) and sulfur (S).
  • R is a general abbreviation that represents a substituent group that is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl groups.
  • salts includes salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
  • inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, Journal of Pharmaceutical Science, 66: 1- 19 (1977)).
  • Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • the present invention provides compounds, which are in a prodrug form.
  • Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
  • prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C).
  • radioactive isotopes such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C).
  • AU isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
  • R 1 , R 2 , R 3 and R 4 are members independently selected from H, F, CF 3 , substituted or unsubstituted C 1 -C 4 alkyl, unsubstituted 4- to 7- membered cycloalkyl and unsubstituted 4- to 7- membered heterocycloalkyl.
  • the symbol A represents a member selected from:
  • R 5 is a member selected from OR*, NR*R**, SR*, -S(O)R*, -S(O) 2 R*, - S(O) 2 NR*R**, -C(O)R*, -C(O)OR*, -C(O)NR*R**, C 1 -C 4 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • Each R* and R** is a member independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • the index q represents a member selected from the integers from 0 to 2.
  • R 6 and R 6 are independently selected from H, C 1 -C 4 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 5 and R 6 are optionally joined to form a member selected from substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl.
  • the symbol B represents a member selected from:
  • the symbol X represents a member selected from O and S.
  • the symbol Y represents a member selected from CH and N.
  • the index s represents an integer greater than 0, sufficient to satisfy the valence requirements of the ring atoms.
  • Each R 7 is independently selected from H, OR 8 , NR 9 R 10 , SO 2 NR 9 R 10 , cyano, halogen, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 8 is selected from H, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R and R ° are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • Each R 11 is selected from H, OR 13 , NR 14 R 15 , SO 2 NR 14 R 15 , cyano, halogen, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 13 is a member selected from H, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 14 and R 15 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 14 and R 15 together with the nitrogen to which they can be bound, can be optionally joined to form a substituted or unsubstituted 5- to 7-membered ring.
  • the index r represents a member selected from the integers from 0 to 2.
  • the index p represents a member selected from the integers from 0 to 1.
  • R 12 is a member selected from C 1 -C 4 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • the indices m and n can independently represent an integer selected from 0 to 2, such that when a member selected from m and n can be greater than 1, each R 1 and R 2 ; R 3 and R 4 , respectively, can be independently selected.
  • the indices m and n can be 0.
  • the symbol A is a member selected from
  • J is a member selected from OR*, NR*R**, SR*, -S(O)R*, -S(O) 2 R*, -S(O) 2 NR*R**, - C(O)R*, -C(O)OR*, -C(O)NR*R**, C 1 -C 4 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • Each R* and R** is a member independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 18 and R 19 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted aryl.
  • R 18 and R 19 together with each carbon to which each of R 18 and R 19 are attached, are optionally joined to form a member selected from substituted or unsubstituted 3- to 7-member cycloalkyl moiety and substituted or unsubstituted 5- to 7-member heterocycloalkyl moiety.
  • the index t is an integer selected from 0 to 4, such that when t is greater than 1, each R 18 and R 19 is independently selected.
  • R 6 and R 18 together with the atoms to which R 6 and R 18 are attached, are optionally joined to form a substituted or unsubstituted 4- to 7-member heterocycloalkyl moiety.
  • R 6 and J together with the atoms to which R 6 and J are attached, are optionally joined to form a member selected from substituted or unsubstituted 3- to 7-member cycloalkyl moiety and substituted or unsubstituted 5- to 7- member heterocycloalkyl moiety.
  • J is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkylthio, substituted or unsubstituted cycloalkylamino, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkyloxy, substituted or unsubstituted heterocycloalkylthio, substituted or unsubstituted heterocycloalkylamino, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted arylthio, substituted or unsubstituted arylamino, substituted or unsubstituted heteroaryl, substituted or
  • J is substituted or unsubstituted aryl.
  • J is substituted or unsubstituted phenyl.
  • a substituent on the substituted phenyl is a member selected from halogen, methyl, trifluoromethyl, ethyl, t-butyl, methoxy and chlorothienyl.
  • substituted phenyl is a member selected from chlorophenyl, fluorophenyl, dichlorophenyl, difluorophenyl, chlorofluorophenyl, trifluoromethylfluorophenyl, trifluoromethylchlorophenyl, t-butylchlorophenyl, t-butylfluorophenyl, methylchlorophenyl, methylfluorophenyl, methoxychlorophenyl, and methoxyfluorophenyl.
  • J is substituted or unsubstituted aryloxy.
  • J is substituted or unsubstituted phenoxy.
  • a substituent on the substituted phenoxy is a member selected from halogen, methyl, trifluoromethyl, ethyl, t-butyl, methoxy and chlorothienyl.
  • substituted phenoxy is a member selected from chlorophenoxy, fluorophenoxy, dichlorophenoxy, difluorophenoxy, chlorofluorophenoxy, trifluoromethylfluorophenoxy, trifluoromethylchlorophenoxy, t-butylchlorophenoxy, t-butylfluorophenoxy, methylchlorophenoxy, methylfluorophenoxy, methoxychlorophenoxy, and methoxyfluorophenoxy.
  • J is substituted or unsubstituted phenylamino.
  • a substituent on the substituted phenylamino is a member selected from halogen, methyl, trifluoromethyl, ethyl, t-butyl, methoxy and chlorothienyl.
  • substituted phenylamino is a member selected from chlorophenylamino, fluorophenylamino, dichlorophenylamino, difluorophenylamino, chlorofluorophenylamino, trifluoromethylfluorophenylamino, trifluoromethylchlorophenylamino, t-butylchlorophenylamino, t-butylfluorophenylamino, methylchlorophenylamino, methylfluorophenylamino, methoxychlorophenylamino, and methoxyfluorophenylamino .
  • J is substituted or unsubstituted pyridinyloxy.
  • J is unsubstituted pyridinyloxy.
  • a substituent on the substituted pyridinyloxy is a member selected from halogen, methyl, trifluoromethyl, ethyl, t-butyl, methoxy and chlorothienyl.
  • substituted pyridinyloxy is a member selected from chloropyridinyloxy, fluoropyridinyloxy, dichloropyridinyloxy, difluoropyridinyloxy, chlorofluoropyridinyloxy, trifluoromethylfluoro pyridinyloxy, trifluoromethylchloropyridinyloxy, t- butylchloropyridinyloxy, t-butylfluoropyridinyloxy, methylchloropyridinyloxy, methylfluoropyridinyloxy, methoxychloropyridinyloxy, and methoxyfluoropyridinyloxy.
  • J is substituted or unsubstituted benzo[l,4]dioxin-2- yl.
  • J is unsubstituted benzo[l,4]dioxin-2-yl.
  • a substituent on the substituted benzo[l,4]dioxin-2-yl is a member selected from halogen, methyl, trifluoromethyl, ethyl, t-butyl, methoxy and chlorothienyl.
  • substituted benzo[l,4]dioxin-2-yl is a member selected from chlorobenzo[l,4]dioxin-2-yl, fluorobenzo[l,4]dioxin-2-yl, dichlorobenzo[l,4]dioxin-2-yl, difluorobenzo[l ,4]dioxin-2-yl, chlorofluorobenzo[l ,4]dioxin-2-yl, trifluoromethylfluorobenzo[l ,4]dioxin-2-yl, trifluoromethylchlorobenzo[l ,4]dioxin-2-yl, t- butylchlorobenzo[l,4]dioxin-2-yl, t-butylfluorobenzo[l,4]dioxin-2-yl, methylchlorobenzo[l ,4]dioxin-2-yl, methylfluorobenzo[l ,
  • J is substituted or unsubstituted alkyl.
  • J is a member selected from methyl, ethyl, propyl, and 3,3 dimethylbutyl.
  • a substituent on the substituted alkyl is a member selected from halogen, methyl, trifluoromethyl, ethyl, t-butyl, methoxy, and chlorothienyl.
  • J is a member selected from
  • t is 1, R 18 is H and R 19 is H. In an exemplary embodiment, t is 1, R 18 is CH 3 and R 19 is H. In an exemplary embodiment, t is 1, R 18 is CH 3 and R 19 is CH 3 . In an exemplary embodiment, t is 1, R 18 and R 19 , along with the atom to which they are attached, are joined to form a member selected from a cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl ring. In an exemplary embodiment, t is 1, R and R 19 , along with the atom to which they are attached, are joined to form a cyclobutyl ring.
  • t is 2, and each R 18 is H and each R 19 is H. In an exemplary embodiment, t is 2, and at least one R 18 is CH 3 and at least one R 19 is H. In an exemplary embodiment, t is 2, and at least one R 18 is CH 3 and at least one R 19 is CH 3 .
  • t is 2, R 18 and R 19 , along with the atom to which they are attached, are joined to form a member selected from a cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl ring. In an exemplary embodiment, t is 2, R 18 and R 19 , along with the atom to which they are attached, are joined to form a cyclobutyl ring.
  • R 6 and R 18 together with the atoms to which R 6 and R 18 are attached, are joined to form a member selected from a substituted or unsubstituted azetidinyl, pyrrolidinyl, piperazinyl, or piperidinyl moiety.
  • R 6 and R 18 together with the atoms to which R 6 and R 18 are attached, are joined to form an unsubstituted azetidinyl moiety.
  • R 6 and R 18 together with the atoms to which R 6 and R 18 are attached, are joined to form an unsubstituted piperidinyl moiety.
  • R 6 and J together with the atoms to which R 6 and J are attached, are joined to form a member selected from substituted or unsubstituted 3- to 7- member cycloalkyl moiety and substituted or unsubstituted 5- to 7-meniber heterocycloalkyl moiety.
  • R 6 and J, together with the atoms to which R 6 and J are attached are joined to form a member selected from a substituted or unsubstituted azetidinyl, pyrrolidinyl, piperazinyl, or piperidinyl moiety.
  • the symbol A is a member selected from
  • the symbol A is a member selected from
  • R 6 is CH 3 .
  • the compound has a structure according to Formulae (II), (Ha), (III) or (Ilia):
  • R 20 and R 21 are members independently selected from H, OR 22 , NR 23 R 24 , SO 2 NR 23 R 24 , cyano, halogen, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 22 is a member selected from H, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 23 and R 24 are members independently selected from H 3 substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 2 is H and R 21 is halogen.
  • R is halogen and R is H.
  • R is H and R is Cl.
  • R is Cl and R is H.
  • R 21 is F.
  • R 20 is F and R 21 is H. In an exemplary embodiment, R 20 is Cl and R 21 is F. In an exemplary embodiment, R 20 is F and R 21 is F. In an exemplary embodiment, R 20 is Cl and R 21 is Cl.
  • the compound has a structure according to Formulae (II), (Ha), (III) or (Ilia) wherein the combination of R 20 and R 21 are as described in paragraph 88 and wherein J is a member selected from a species described in paragraph 71, 72, 73, 74, 75, 76, 77, 78 or 79.
  • the compound has the formula:
  • R 20 and R 21 are as described above.
  • the compound has a formula which is a member selected from: wherein the symbol A is a member selected from
  • the compound has a formula which is a member selected from:
  • B is a member selected from:
  • the index s is an integer greater than 0, sufficient to satisfy the valence requirements of the ring atoms.
  • Each R 7 is a member independently selected from H, OR 8 , NR 9 R 10 , SO 2 NR 9 R 10 , cyano, halogen, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 8 is a member selected from H, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 9 and R 10 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • the compound has a formula selected from:
  • J is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 18 and R 19 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted aryl.
  • R 18 and R 19 together with each carbon to which each of R 18 and R 19 are attached, are optionally joined to form a member selected from a substituted or unsubstituted 3- to 7-member cycloalkyl moiety and substituted or unsubstituted 5- to 7-member heterocycloalkyl moiety.
  • the index t is an integer selected from 0 to 4, such that when t is greater than 1, each R 18 and R 19 is independently selected.
  • R 20 and R 21 are members independently selected from H, OR 22 , NR 23 R 24 , SO 2 NR 23 R 24 , cyano, halogen, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 22 is a member selected from H, CF 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 23 and R 24 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • R 23 and R 24 together with the nitrogen to which they are bound, are optionally joined to form a substituted or unsubstituted 5- to 7-membered ring.
  • J is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkylthio, substituted or unsubstituted cycloalkylamino, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkyloxy, substituted or unsubstituted heterocycloalkylthio, substituted or unsubstituted heterocycloalkylamino, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted arylthio, substituted or unsubstituted arylamino, substituted or unsubstituted heteroaryl, substituted or
  • Representative compounds of the invention are set forth in Table II.
  • the compound is a compound set forth in Table II.
  • compounds of the invention that are poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers and higher homologs of the compounds of the invention or reactive analogues thereof.
  • the poly- and multi-valent species can be assembled from a single species or more than one species of the invention.
  • a dimeric construct can be "homo-dimeric” or "heterodimeric.”
  • poly- and multi-valent constructs in which a compound of the invention or a reactive analogue thereof, can be attached to an oligomeric or polymeric framework e.g., polylysine, dextran, hydroxyethyl starch and the like
  • the framework is preferably polyfunctional (i.e. having an array of reactive sites for attaching compounds of the invention).
  • the framework can be derivatized with a single species of the invention or more than one species of the invention.
  • the present invention includes compounds within a motif described herein, which are functionalized to afford compounds having water-solubility that is enhanced relative to analogous compounds that are not similarly functionalized.
  • any of the substituents set forth herein can be replaced with analogous radicals that have enhanced water solubility.
  • additional water solubility is imparted by substitution at a site not essential for the activity towards the ion channel of the compounds set forth herein with a moiety that enhances the water solubility of the parent compounds.
  • Such methods include, but are not limited to, functionalizing an organic nucleus with a permanently charged moiety, e.g., quaternary ammonium, or a group that is charged at a physiologically relevant pH, e.g. carboxylic acid, amine.
  • Other methods include, appending to the organic nucleus hydroxyl- or amine-containing groups, e.g. alcohols, polyols, polyethers, and the like.
  • Representative examples include, but are not limited to, polylysine, polyethyleneimine, poly(ethyleneglycol) and poly(propyleneglycol). Suitable functionalization chemistries and strategies for these compounds are known in the art. See, for example, Dunn, R. L., et al, Eds. Polymeric Drugs and Drug Delivery Systems, ACS Symposium Series Vol. 469, American Chemical Society, Washington, D.C. 1991.
  • the invention provides a pharmaceutical formulation comprising a compound according a formula described herein.
  • the invention provides a pharmaceutical formulation comprising a compound described herein.
  • the invention provides a pharmaceutical formulation comprising a compound according to Formula I.
  • the invention provides a method of modulating the activity of a sodium channel in a subject.
  • This method comprises administering to a subject an amount of a compound according a formula described herein sufficient to modulate said activity.
  • the method comprises administering to a subject an amount of a compound described herein sufficient to modulate said activity.
  • This method comprises administering to a subject an amount of a compound according a formula described herein sufficient to modulate said activity.
  • the method comprises administering to a subject an amount of a compound according to Formula I sufficient to modulate said activity.
  • the invention provides a method of ameliorating or alleviating a condition in a subject.
  • the condition can be a member selected from pain, irritable bowel syndrome, Crohn's disease, epilepsy, seizures multiple sclerosis, bipolar depression and tachy-arrhythmias.
  • the method includes administering to the subject an amount of the compound described herein sufficient to ameliorate or alleviate the condition.
  • the condition is pain
  • the pain can be a member selected from acute pain, chronic pain, visceral pain, inflammatory pain and neuropathic pain. Exemplary aspects of this method are described in greater detail in section VI, herein.
  • Compound 5 was synthesized by reacting 4 with 2-bromoethanol and chlorosulfonyl isocyanate.
  • Compound 7 was formed by the reaction of an appropriately substituted amine 6 with substituted amino aryl sulfonamide 5 in an organic solvent, such as acetonitrile, in the presence of pyridine or triethylamine at an elevated temperature, e.g., 90 0 C.
  • Oxazolidinone 8 was synthesized by reacting amine 6 with the product of the reaction of 2-bromoethanol and chlorosulfonyl isocyanate in the presence of a base such as triethylamine. The reaction of the oxazolidinone 8 with 4 provides 7.
  • a typical procedure for the synthesis of 10 involved the reaction of a sulfonyl chloride 9 with an amine 6 in the presence of a base such as triethyl amine.
  • the sulfonyl chloride 9 was prepared by reacting a substituted aryl amine 4 with NaNO 2 in the presence of CuCl 2 followed by reaction with sulfur dioxide.
  • the activity of sodium channels can be assessed using a variety of in vitro assays, including but not limited to, measuring ion flux, measuring transmembrane potential, and/or measuring ionic current. Measurement of ionic fluxes can be accomplished by measuring changes in the concentration of the permeant species or by tracking the movement of small amounts of an appropriately permeant radioactive tracer. Transmembrane potential can be assessed with voltage-sensitive fluorescent dyes or, more sensitively, with electrophysiological methods.
  • Determination of the effectiveness of compounds as ex vivo blockers of sodium channels can be assessed by the inhibition pf compound action potential propagation in isolated nerve preparations (Kourtney and Stricharz, LOCAL ANESTHETICS, Springer-Verlag, New York, 1987).
  • a number of experimental models in the rat are appropriate for assessing the in vivo efficacy of the compounds of the invention.
  • the neuropathic pain model produced by the tight ligation of spinal nerves described by Kim et al, Pain, 50: 355- 363 (1992)
  • Mechanical sensitivity can also be assessed using a procedure described by Chaplan et al, J. Neurosci. Methods, 53: 55-63 (1994). Other assays of use are known to those of skill in the art.
  • TTX-sensitive sodium channels can be tested using biologically active recombinant channels, or naturally occurring TTX-sensitive sodium channels, or by using native cells, like neurons expressing a TTX-sensitive sodium current.
  • TTX-sensitive sodium channels can be isolated, co-expressed or expressed in a cell, or expressed in a membrane derived from a cell.
  • TTX-sensitive sodium channels are generally expressed alone to form a homomeric sodium channel or may be co-expressed with a second subunit ⁇ e.g., an auxiliary beta subunit) so as to form a heteromeric sodium channel.
  • the TTX-sensitive sodium channels are stably expressed in HEK-293 cells, an example of an effective mammalian expression system.
  • Modulation can be tested using one of the in vitro or in vivo assays described above. Samples or assays that are treated with a potential sodium channel inhibitor are compared to control samples without the test compound, to examine the extent of modulation. Control samples (untreated with inhibitors) are assigned a relative sodium channel activity value of 100. Inhibition of TTX-sensitive sodium channels is achieved when the sodium channel activity value relative to the control is less than 70%, preferably less than 40% and still more preferably, less than 30%. Compounds that decrease the flux of ions will cause a detectable decrease in the ion current density by decreasing the probability of a TTX-sensitive sodium channel being open, by decreasing conductance through the channel, decreasing the number of channels, or decreasing the expression of channels.
  • Changes in ion flux may be assessed by determining changes in polarization (/. e. , electrical potential) of the cell or membrane expressing the sodium channel.
  • a preferred means to determine changes in cellular polarization is by measuring changes in current or voltage with the voltage-clamp and patch-clamp techniques, using the "cell-attached” mode, the "inside-out” mode, the “outside-out” mode, the “perforated patch” mode, the "whole cell” mode or other means of controlling or measuring changes in transmembrane potential ⁇ see, e.g., Ackerman et al, New Engl. J. Med., 336: 1575-1595 (1997)).
  • Assays for compounds capable of inhibiting or increasing sodium flux through the channel proteins can be performed by application of the compounds to a bath solution in contact with and comprising cells having a channel of the present invention (see, e.g., Blatz et al, Nature 323: 718-720 (1986); Park, J. Physiol. 481: 555-570 (1994)).
  • the compounds to be tested are present in the range from about 1 nM to about 100 mM, preferably from about 1 nM to about 30 ⁇ M. In an exemplary embodiment, the compounds to be tested are present in the range from about 1 nM to about 3 ⁇ M.
  • test compounds upon the function of the channels can be measured by changes in the electrical currents or ionic flux or by the consequences of changes in currents and flux.
  • Changes in electrical current or ionic flux are measured by either increases or decreases in flux of ions such as sodium or guanidinium ions (see U.S.
  • Patent No. 5,688,830 The cations can be measured in a variety of standard ways. They can be measured directly by concentration changes of the ions or indirectly by membrane potential or by using radioactive ions. Consequences of the test compound on ion flux can be quite varied. Accordingly, any suitable physiological change can be used to assess the influence of a test compound on the channels of this invention. The effects of a test compound can be measured by a toxin-binding assay.
  • High throughput screening is of use in identifying promising candidate compounds of the invention.
  • an agent that modifies the gating of the channel e.g., pyrethroids, alpha-scorpion toxins, beta-scorpion toxins, batrachotoxin, etc.
  • agents modify the gating of sodium channels and keep the pore open for extended periods of time.
  • sodium channels are primarily selective for sodium, other ionic species can permeate the channel.
  • TTX-sensitive sodium channel blocking agents of the invention can also be assayed against non-specific blockers of sodium channels, such as tetracaine, mexilitine, and flecainide.
  • compositions of VGSC Inhibitors [0118]
  • the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of the invention described herein.
  • the compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
  • the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
  • the compounds described herein can be administered by inhalation, for example, intranasally.
  • the compounds of the present invention can be administered transdermally.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and either a compound described herein, or a pharmaceutically acceptable salt of a compound described herein.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from 5% or 10% to 70% of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • the present invention provides methods for decreasing ion flow through voltage gated sodium channels in a cell, comprising contacting a cell containing the target ion channels with a sodium channel-inhibiting amount of a compound described herein.
  • the methods provided in this aspect of the invention are useful for the diagnosis of conditions that can be treated by inhibiting ion flux through voltage gated sodium channels, or for determining if a patient will be responsive to therapeutic agents, which act by inhibiting sodium channels.
  • the present invention provides a method for the treatment of a disorder or condition through inhibition of a voltage ' gated sodium channel.
  • a subject in need of such treatment is administered an effective amount of a compound described herein and/or according to a formula described herein.
  • the compounds provided herein are used to treat a disorder or condition by inhibiting an ion channel of the VGSC family.
  • the compounds provided herein are useful as sodium channel inhibitors and find therapeutic utility via inhibition of VGSCs in the treatment of diseases or conditions.
  • the sodium channels that are typically inhibited are described herein as VGSCs such as the Na v l.l channel.
  • the compounds of the invention are particularly preferred for use in the treating, preventing or ameliorating pain or seizures.
  • the method includes administering to a patient in need of such treatment, a therapeutically effective amount of a compound described herein and/or according to a formula described herein, or a pharmaceutically acceptable salt thereof.
  • the compounds, compositions and methods of the present invention are of particular use in treating pain, including both inflammatory and neuropathic pain.
  • Exemplary forms of pain treated by a compound of the invention include, postoperative pain, osteoarthritis pain, pain associated with metastatic cancer, neuropathy secondary to metastatic inflammation, trigeminal neuralgia, glossopharangyl neuralgia, adiposis dolorosa, burn pain, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, pain following stroke, thalamic lesions, radiculopathy, and other forms of neuralgic, neuropathic, and idiopathic pain syndromes.
  • Idiopathic pain is pain of unknown origin, for example, phantom limb pain.
  • Neuropathic pain is generally caused by injury or infection of the peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis.
  • Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies.
  • any VGSC inhibitory substance possessed of satisfactory VGSC modulating activity coupled with favorable intracranial transfer kinetics and metabolic stability is expected to show efficacy in central nervous system (CNS) diseases and disorders such as central nervous system ischemia, central nervous system trauma (e.g. brain trauma, spinal cord injury, whiplash injury, etc.), epilepsy, seizures, neurodegenerative diseases (e.g. amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Huntington's chorea, Parkinson's disease, diabetic neuropathy, etc.), vascular dementia (e.g. multi-infarct dementia,
  • CNS central nervous system
  • Binswanger's disease, etc. manic-depressive psychosis, depression, schizophrenia, chronic pain, trigeminal neuralgia, migraine, ataxia, bipolar disorder, spasticity, mood disorders, psychotic disorders, hearing and vision loss, age-related memory loss, learning deficiencies, anxiety and cerebral edema.
  • the compounds utilized in the method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily.
  • a daily dose range of about 0.1 mg/kg to about 100 mg/kg is more typical.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
  • mp melting point
  • L liter(s)
  • mL milliliters
  • mmol millimoles
  • g grams
  • mg milligrams
  • min minutes
  • LC-MS liquid chromatography-mass spectrometry
  • h hours
  • PS polystyrene
  • DIE diisopropylethylamine
  • Example 3 provides methods for testing the efficacy of the compounds of the invention.
  • HEK Human Embryonic Kidney
  • HEK cells stably transfected with hSCN3A were maintained in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum and 400 ⁇ g/ml G418 sulfate in an incubator at 37 0 C with a humidified atmosphere of 10% CO 2 .
  • HTS cells were harvested from flasks by trypsinization and replated in an appropriate multi-well plate
  • Pipettes were filled with an intracellular solution of the following composition: 135 mM CsF, 5 mM CsCl, 2 mM MgCl 2 , 10 mM EGTA, 10 mM HEPES, pH 7.3 to 7.4, and had a resistance of 1 to 2 mega ohms.
  • the osmolarity of the extracellular and intracellular solutions was 300 mmol/kg and 295 mmol/kg, respectively. All recordings were made at room temperature (22-24°C) using AXOPATCH 200B amplifiers and PCLAMP software (Axon Instruments, Burlingame, CA) or PatchXpress 7000 hardware and associated software (Axon Instruments, Burlingame, CA).
  • hSCN3 A currents in HEK cells were measured using the whole-cell configuration of the patch-clamp technique (Hamill et al., 1981). Uncompensated series resistance was typically 2 to 5 mega ohms and >85% series resistance compensation (50% for PatchXpress) was routinely achieved. As a result, voltage errors were negligible and no correction was applied. Current records were acquired at 20 to 50 KHz and filtered at 5 to 10 KHz.
  • Efflux was initiated by addition of buffer containing any necessary chemical activators (e.g., 100 ⁇ M veratridine, 10 - 20 ⁇ g/ml Lqh scorpion venom, etc.). Various concentrations of test compounds or reference sodium channel blockers were added concurrently with the initiation of efflux. Efflux was allowed to progress for a defined period of time, typically 30 - 90 minutes, at 37 0 C in a humidified 10% CO 2 atmosphere. Stimulated efflux was determined by collecting the extracellular solution and transferring to a multiwell plate for scintillation counting. Residual intracellular radioactivity was also determined by scintillation counting following lysis of the cells in the assay plate. Inhibition of efflux was determined by comparing efflux in the presence of test compounds to efflux in untreated control cells.
  • any necessary chemical activators e.g., 100 ⁇ M veratridine, 10 - 20 ⁇ g/ml Lqh scorpion venom, etc.
  • + indicates IC5O>1 ⁇ M
  • ++ indicates 1 ⁇ M>IC50>0.5 ⁇ M
  • +++ indicates 0.5 ⁇ M>IC50>0.1 ⁇ M
  • ++++ indicates IC50 ⁇ 0.1 ⁇ M

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne des composés, compositions et procédés utiles dans le traitement de maladies par inhibition de courants d’ions sodium à travers les canaux sodiques sensibles au voltage. Plus particulièrement, la présente invention concerne des sulfonamides d’aryle substitués, des compositions comprenant ces composés, ainsi que des procédés d’utilisation de ces composés ou compositions dans le traitement de troubles du système nerveux central ou périphérique, particulièrement de la douleur et de la douleur chronique par blocage des canaux sodiques associé au début ou à la récurrence des maladies indiquées. Les composés, compositions et procédés selon la présente invention sont particulièrement utiles dans le traitement de la douleur inflammatoire ou neuropathique, par inhibition du courant d’ions à travers les canaux sodiques sensibles au voltage.
PCT/US2006/042882 2005-11-02 2006-11-02 Inhibiteurs de canaux ioniques WO2007056099A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06827413A EP1945029A4 (fr) 2005-11-02 2006-11-02 Inhibiteurs de canaux ioniques
AU2006311954A AU2006311954A1 (en) 2005-11-02 2006-11-02 Inhibitors of ion channels
JP2008539041A JP2009514868A (ja) 2005-11-02 2006-11-02 イオンチャネルの阻害剤
CA002628312A CA2628312A1 (fr) 2005-11-02 2006-11-02 Inhibiteurs de canaux ioniques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73254305P 2005-11-02 2005-11-02
US60/732,543 2005-11-02

Publications (2)

Publication Number Publication Date
WO2007056099A2 true WO2007056099A2 (fr) 2007-05-18
WO2007056099A3 WO2007056099A3 (fr) 2007-07-12

Family

ID=38023817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042882 WO2007056099A2 (fr) 2005-11-02 2006-11-02 Inhibiteurs de canaux ioniques

Country Status (6)

Country Link
US (2) US7705158B2 (fr)
EP (1) EP1945029A4 (fr)
JP (1) JP2009514868A (fr)
AU (1) AU2006311954A1 (fr)
CA (1) CA2628312A1 (fr)
WO (1) WO2007056099A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015273A2 (fr) * 2007-07-24 2009-01-29 Roamware, Inc. Intelligence prédictive
WO2018130625A1 (fr) * 2017-01-12 2018-07-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Benzènedisulfonamide pour le traitement du cancer

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012241A1 (fr) * 2007-07-13 2009-01-22 Icagen, Inc. Inhibiteurs de canaux sodiques
WO2010033824A1 (fr) * 2008-09-19 2010-03-25 Icagen, Inc. Dérivés de sulfamide utilisables en tant qu'inhibiteurs des canaux ioniques
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6172085B1 (en) 1996-08-29 2001-01-09 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2826594A (en) * 1955-09-27 1958-03-11 American Cyanamid Co Sulfamoylsulfanilamides and method of preparing the same
JP3690831B2 (ja) * 1995-02-27 2005-08-31 エーザイ株式会社 インドール含有スルホンアミド誘導体
JPH115370A (ja) * 1997-06-17 1999-01-12 Asahi Denka Kogyo Kk 感熱記録材料
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
JP4007743B2 (ja) * 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
TW200524888A (en) * 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
JP2007261945A (ja) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6172085B1 (en) 1996-08-29 2001-01-09 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
"Harrison's Principles of Internal Medicine", pages: 93 - 98
"Polymeric Drugs and Drug Delivery Systems", vol. 469, 1991, AMERICAN CHEMICAL SOCIETY
ACKERMAN ET AL., NEW ENGL. J MED., vol. 336, 1997, pages 1575 - 1595
BERGE ET AL., JOURNAL OFPHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19
BERKOVIC, S. F. ET AL., ANN. NEUROL., vol. 55, 2004, pages 550 - 557
BLACK ET AL., PAIN, vol. 108, no. 3, 2004, pages 237 - 47
BLACK, JA ET AL., PROC. NATL. ACAD SCI. USA, vol. 97, no. 21, 2000, pages 11598 - 602
BLATZ ET AL., NATURE, vol. 323, 1986, pages 718 - 720
BOUCHER TJ, CURR. OPIN. PHARMACOL., vol. 1, no. 1, 2001, pages 66 - 72
CANNON, SC, KIDNEY INT., vol. 57, no. 3, 2000, pages 772 - 9
CHAPLAN ET AL., J NEUROSCI. METHODS, vol. 53, 1994, pages 55 - 63
CLAES, L ET AL., AM. J HUM. GENET., vol. 68, 2001, pages 1327 - 1332
DANIEL ET AL., J PHARMACOL. METH., vol. 25, 1991, pages 185 - 193
DESAPHY JF ET AL., J PHYSIOL., vol. 554, no. 2, 2004, pages 321 - 34
DEVOR ET AL., J NEUROSCI., vol. 132, 1993, pages 1976
ESCAYG, A., AM. J HUM. GENET., vol. 68, 2001, pages 866 - 873
GOULD ET AL., BRAIN RES., vol. 824, no. 2, 1999, pages 296 - 9
HAINS BC, J NEUROSCI., vol. 23, no. 26, 2003, pages 8881 - 92
HAMILL ET AL., PFLUGERS. ARCHIV., vol. 391, 1981, pages 85
HOLEVINSKY ET AL., J MEMBRANE BIOLOGY, vol. 137, 1994, pages 59 - 70
HUBNER CA, JENTSCH TJ, HUM. MOL. GENET., vol. 11, no. 20, 2002, pages 2435 - 45
HUDSON AJ, BRAIN, vol. 118, no. 2, 1995, pages 547 - 63
KIM ET AL., PAIN, vol. 50, 1992, pages 355 - 363
KRETSCHMER ET AL., ACTA. NEUROCHIR. (WIEN, vol. 144, no. 8, 2002, pages 803 - 10
LAIRD JM ET AL., J NEUROSCI., vol. 22, no. 19, 2002, pages 8352 - 6
LEFFLER A ET AL., J NEUROPHYSIOL., vol. 88, no. 2, 2002, pages 650 - 8
LEGROUX-CREPEL ET AL., ANN. DERMATOL VENEREAL., vol. 130, pages 429 - 433
LIU H ET AL., AM. J PHARMACOGENOMICS, vol. 3, no. 3, 2003, pages 173 - 9
LOSSIN, C, NEURON, vol. 34, 2002, pages 877 - 884
MANNION ET AL., LANCET, vol. 353, 1999, pages 1959 - 1964
MEISLER MH, GENETICA, vol. 122, no. 1, 2004, pages 37 - 45
NASSAR ET AL., PROC NATL ACAD SCI USA, vol. 101, no. 34, 2004, pages 12706 - 11
NOBLE D., PROC. NATL. ACAD SCI. USA, vol. 99, no. 9, 2002, pages 5755 - 6
PARK, J, PHYSIOL, vol. 481, 1994, pages 555 - 570
PLANELLS-CASES R ET AL., BIOPHYS. J., vol. 78, no. 6, 2000, pages 2878 - 91
PTACEK, L. J., AM. J HUM. GENET., vol. 49, 1991, pages 851 - 854
SCHALLER KL, CEREBELLUM, vol. 2, no. 1, 2003, pages 2 - 9
SHAH BS, PHYSIOL., vol. 534, no. 3, 2001, pages 763 - 76
SRIVATSA U ET AL., CURR. CARDIOL. REP., vol. 4, no. 5, 2002, pages 401 - 10
TOLEDO-ARAL ET AL., PROC. NATL. ACAD SCI. USA, vol. 94, no. 4, 1997, pages 1527 - 1532
TZOUMAKA E, J NEUROSCI. RES., vol. 60, no. 1, 2000, pages 37 - 44
VESTERGARRD-BOGIND ET AL., J MEMBRANE BIOL., vol. 88, 1988, pages 67 - 75
WILLIAMS ET AL., J OFMED. CHEM., vol. 42, 1999, pages 1481 - 1485
WOOD ET AL., J NEUROBIOL., vol. 61, no. 1, 2004, pages 55 - 71
WOOD, JN ET AL., J NEUROBIOL., vol. 61, no. 1, 2004, pages 55 - 71
YANG ET AL., J MED GENET., vol. 41, no. 3, 2004, pages 171 - 4
YOGEESWARI ET AL., CURR. DRUG TARGETS, vol. 5, no. 7, 2004, pages 589 - 602

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015273A2 (fr) * 2007-07-24 2009-01-29 Roamware, Inc. Intelligence prédictive
WO2018130625A1 (fr) * 2017-01-12 2018-07-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Benzènedisulfonamide pour le traitement du cancer
EP3351544A1 (fr) * 2017-01-12 2018-07-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzène disulfonamide pour le traitement du cancer
US10913710B2 (en) 2017-01-12 2021-02-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Benzene disulfonamide for the treatment of cancer

Also Published As

Publication number Publication date
JP2009514868A (ja) 2009-04-09
EP1945029A2 (fr) 2008-07-23
US7705158B2 (en) 2010-04-27
WO2007056099A3 (fr) 2007-07-12
US20070135493A1 (en) 2007-06-14
CA2628312A1 (fr) 2007-05-18
US8338608B2 (en) 2012-12-25
US20100234343A1 (en) 2010-09-16
EP1945029A4 (fr) 2011-02-02
AU2006311954A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
CA2620179C (fr) Inhibiteurs des canaux sodium sensibles au voltage
CA2681572C (fr) Inhibiteurs de canaux ioniques
US8034954B2 (en) Calcium channel antagonists
JP5463285B2 (ja) ナトリウムチャネル阻害物質
US8338608B2 (en) Inhibitors of ion channels
EP1451173A2 (fr) Piperidines
WO2003037274A2 (fr) Pyrazole-amides et -sulfonamides
US20070197523A1 (en) Calcium channel antagonists
EP1506196A2 (fr) Pyrazolopyrimidines
KR20190007050A (ko) 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
WO2012037351A1 (fr) Composés
AU2004253447A1 (en) Asymmetric benzimidazoles and related compounds as potassium channel modulators
US7205307B2 (en) Pyrimidines as novel openers of potassium ion channels
WO2010033824A1 (fr) Dérivés de sulfamide utilisables en tant qu'inhibiteurs des canaux ioniques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008539041

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2628312

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006311954

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006827413

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006311954

Country of ref document: AU

Date of ref document: 20061102

Kind code of ref document: A